explore -WSS

explore

author：focus 2025-10-02 04:07:43 - browse：3

To much of the public, the promise of telehealth is all about convenience — get the prescription you need quickly, and get it delivered right to your door. But as digital health companies build out their weight loss businesses, capitalizing on the popularity of drugs like Wegovy and Ozempic, they’re courting a very different audience: payers and employers who have a vested interest in preventing quick scripts.

Payers are reeling as they try to figure out how to sustainably cover GLP-1 receptor agonists, a class of remarkably effective but expensive obesity and type 2 diabetes drugs. So in the last six months, digital health companies including Teladoc, Found, Hello Alpha, and Calibrate have advanced enterprise products that pair virtual visits and prescriptions with lifestyle coaching. Their hope is that more and more payers and employers will offer their programs as a way to support lasting weight loss and metabolic health — or even require them if patients want their drugs reimbursed.

The competition is growing quickly. Telehealth companies once focused exclusively on consumers are now marketing to payers. Enterprise programs for chronic care management are promoting new services to support patients on obesity drugs. And companies like Noom and WeightWatchers, which have built gargantuan weight loss businesses for consumers and businesses alike, are starting to prescribe the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Humana cuts profit projections as Medicare Advantage costs soar

WSS

Pfizer is about to make a big push in cancer. Will investors listen?

Medicare Advantage today, explained in one chart

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Neuroscience renaissance leads to new crop of psychiatric drugs

NEJM study measures Covid brain fog, impact on IQ

Why doctors need education on FDA device approval process

entertainment

explore

entertainment

Walensky prepares to leave CDC — and Congress — behind

Think you might have Covid

Dobbs anniversary: the lost opportunity of abortion as health care

Biotech venture capitalists face new demands from investors

Peter Hotez and the public health issue of online harassment

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

How one medical school became remarkably diverse

How digital therapeutics firms are pivoting after Pear's bankruptcy

Walensky prepares to leave CDC — and Congress — behind

Elisabeth Bik tackles the widespread issue of research misconduct

hotspot

'Vaccine

Francis Collins on trust in science and how Covid communications failed

Readout Newsletter: Merck, J&J, and long Covid

Humana cuts profit projections as Medicare Advantage costs soar

NIH director takes cautious approach to Biden drug pricing priority

Independent physicians launch a new lobbying group

focus

entertainment

hotspot

Wikipedia